| New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. | |
| | |
MedLine Citation:
|
PMID: 15979104 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of non-dopaminergic therapies for the treatment of Parkinson's disease (PD) has attracted much interest in recent years. Among new different classes of drugs, adenosine A2A receptor antagonists have emerged as best candidates. The present review will provide an updated summary of the results reported in literature concerning the effects of adenosine A2A antagonists in rodent and primate models of PD. These results show that A2A receptor antagonists improve motor deficits without inducing dyskinesia and counteract parkinsonian tremor. In progress clinical trials have shown that a low dose of L-DOPA plus KW-6002 produced symptomatic relief no different from that produced by an optimal dose of L-DOPA alone, whereas dyskinesias were reduced rendering this class of compounds particularly attractive. |
| | |
Authors:
|
Annalisa Pinna; Jadwiga Wardas; Nicola Simola; Micaela Morelli |
Related Documents
:
|
9665604 - Motor effects induced by a blockade of adenosine a2a receptors in the caudate-putamen. 8853394 - Adenosine a1 receptor and its gene expression in ventricles from spontaneously hyperten... 7562934 - Ribose-modified adenosine analogues as potential partial agonists for the adenosine rec... 8551344 - The role of adenosine a2a receptors in regulating gabaergic synaptic transmission in st... 17056074 - Alkylene tether-length dependent gamma-aminobutyric acid type a receptor competitive an... 10206994 - A pivotal role for the transmembrane domain in transforming growth factor-beta receptor... |
Publication Detail:
|
Type: Journal Article; Review Date: 2005-06-23 |
Journal Detail:
|
Title: Life sciences Volume: 77 ISSN: 0024-3205 ISO Abbreviation: Life Sci. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-10-17 Completed Date: 2005-11-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375521 Medline TA: Life Sci Country: England |
Other Details:
|
Languages: eng Pagination: 3259-67 Citation Subset: IM |
Affiliation:
|
CNR Institute of Neuroscience-Cagliari section, Italy. apinna@unica.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antiparkinson Agents / therapeutic use* Disease Models, Animal Dyskinesias / drug therapy, metabolism Humans Levodopa / therapeutic use* Parkinson Disease / drug therapy*, metabolism Primates Purines / therapeutic use* Receptor, Adenosine A2A / antagonists & inhibitors*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antiparkinson Agents; 0/Levodopa; 0/Purines; 0/Receptor, Adenosine A2A; 155270-99-8/istradefylline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Co-administration of quercetin and catechin in rats alters their absorption but not their metabolism...
Next Document: Perioperative normothermia depends on intraoperative warming procedure, extent of the surgical inter...